Alkermes’ Alixorexton Shows Statistically Significant Efficacy and Tolerability in Phase 2 Narcolepsy Type 2 Study
Market Chameleon (Wed, 12-Nov 7:58 AM)
ALKS Takes the Initiative: Alkermes Revealed as Offeror in Avadel Takeover Position Disclosure
Market Chameleon (Wed, 5-Nov 10:40 AM)
Alkermes Raises 2025 Outlook on Strong Q3 Performance: Revenue Growth and Pipeline Progress Highlight Investor Confidence
Market Chameleon (Tue, 28-Oct 9:32 AM)
